The myogenic regulatory factors, Mrf4 and Myf5, play a key role in skeletal muscle formation. An enhancer trap approach, devised to isolate positive-acting elements from a 200-kb YAC covering the mouse Mrf4 -Myf5 locus in a C2 myoblast assay, yielded an enhancer, A17, which mapped at À8 kb 5V of Mrf4 and À17 kb 5V of Myf5. An E-box bound by complexes containing the USF transcription factor is critical for enhancer activity. In transgenic mice, A17 gave two distinct and mutually exclusive expression profiles before birth, which correspond to two phases of Mrf4 transcription. Linked to the Tk or Mrf4 minimal promoters, the nlacZ reporter was expressed either in embryonic myotomes, or later in fetal muscle, with the majority of Mrf4 lines showing embryonic expression. When linked to the Myf5 minimal promoter, only fetal muscle expression was detected. These observations identify A17 as a sequence that targets sites of myogenesis in vivo and raise questions about the mutually exclusive modes of expression and possible promoter/enhancer interactions at the Mrf4 -Myf5 locus. D
Introduction
Tissue specification depends on factors that determine the entry of cells into a particular program of differentiation. Skeletal muscle formation is initiated by the myogenic regulatory factors, which control both determination and differentiation of this tissue (reviewed in Buckingham, 2001) . Myf5 is the first member of this basic helix -loophelix family of transcription factors to be expressed in the mouse embryo, where it plays a key role as a determination factor at the onset of myogenesis (Braun et al., 1992; Tajbakhsh et al., 1996a,b) . Later, MyoD also plays this role; when both Myf5 and MyoD genes are mutated, the precursor myoblast population is absent and skeletal muscles do not form (Rudnicki et al., 1993) . Another myogenic factor gene, Mrf4, is linked to Myf5 in the same locus (Braun et al., 1990; Miner and Wold, 1990) . Mrf4 is thought to regulate muscle cell differentiation (Black et al., 1995; Naidu et al., 1995) . This is clearly the function of Myogenin, the fourth member of the family (Hasty et al., 1993; Nabeshima et al., 1993) . However, the differentiation of the early myotomal muscle appears to depend on Mrf4 rather than Myogenin (see Buckingham, 1994; Patapoutian et al., 1995) and in the MyoD À/À /Mrf4 À/À double mutants, most skeletal muscle fibers fail to form (Rawls et al., 1998) , indicating that Myogenin cannot compensate for the absence of both these factors. Recently, the analysis of an allelic series of mutants in the Mrf4-Myf5 locus suggests that Mrf4 also acts as a determination factor at the onset of myogenesis in the embryo (Kassar-Duchossoy, Buckingham and Tajbakhsh, in 
preparation).
Myf5 and Mrf4 have different expression profiles during muscle formation and maturation . Muscle progenitor cells derive from somites, which are formed by progressive segmentation of paraxial mesoderm, following a rostrocaudal gradient on either side of the axial neural tube and notocord, such that the oldest and most mature somites are situated cranially. Newly formed epithelial somites develop an epithelial dermomyotome, adjacent to the surface ectoderm, which gives rise to dermis and muscle, and a ventral sclerotome composed of mesenchymal cells that will contribute to cartilage. Muscle progenitor cells present in the epaxial dermomyotome, adjacent to the axial structures, are the first to delaminate, to form the myotome, a skeletal muscle that underlies the dermomyotome and will later contribute to the deep back muscles. Myf5 is expressed in these cells in the epaxial dermomyotome. Shortly afterwards, both Myf5 and Mrf4 are activated in cells in the opposite, hypaxial, edge of the dermomyotome. These cells will also contribute to the myotome and to the formation of most trunk muscles. As the somite matures, the dermomyotome elongates, such that the first epaxial cells to delaminate are now in the central region of the myotome. This is where differentiation is initiated, with expression of Mrf4. This central or intercalated domain of the dorsal somite is characterized by the expression of Engrailed1, and presents interesting analogies with the adaxial territory of the zebrafish somite (Spörle, 2001) . At the limb level, muscle progenitor cells migrate from the somite into the limb field where they subsequently activate Myf5. Muscle progenitor cells delaminate and move away from anterior somites to form the hypoglossal cord on either side of the axis. These cells, which already express Myf5, contribute to tongue and pharynx muscles. Head muscles, such as those of the jaw, form from unsegmented paraxial mesoderm, from Myf5-positive cells initially present in the branchial arches. As skeletal muscles form and mature during fetal stages, Myf5 continues to be transcribed at a lower level (Tajbakhsh et al., 1996c) Mrf4, on the other hand, is expressed at very low levels in embryonic muscles, with the exception of the myotome; its transcripts accumulate during a second major wave of expression in muscle fibers from fetal stages Hinterberger et al., 1991) .
The control of the Mrf4-Myf5 locus is complex, with some regulatory sequences in the intra-and intergenic regions and others at a considerable distance 5V to the genes. The early expression of Myf5 in the dermomyotome depends on an epaxial enhancer situated just 3V of Mrf4 and 6 kb 5V of Myf5 (Summerbell et al., 2000; Teboul et al., 2002 ). An element that directs transcription of Myf5 in the branchial arches is also present in the intergenic region (Summerbell et al., 2000) . Situated at À58/À48 kb from Myf5 is a sequence containing elements that direct expression of the gene in the limbs, intercalated myotome and epaxial and hypaxial extremities of the mature dermomytome (Buchberger et al., 2003; Hadchouel et al., 2000 Hadchouel et al., , 2003 . Further sequences that direct transcription of Myf5 in the earlier hypaxial dermomyotome are present both within the gene (Summerbell et al., 2000) and at a distance from it (>À88 kb) (Carvajal et al., 2001) . Also, in this far upstream region (À96/À63 kb) are elements that are necessary for the maintenance of Myf5 expression in head and most trunk muscles in the fetus (Carvajal et al., 2001; Hadchouel et al., 2000) . Elements that regulate Mrf4 transcription have been described in the region immediately 5V to the gene. A 6.5-kb sequence 5V to the mouse Mrf4 gene is sufficient to direct the second wave of fetal expression (Patapoutian et al., 1993) and discrete muscle enhancers active in myoblast cultures (Kerkvliet and Hinterberger, 1997 ) and in embryos have been identified in this region (Pin and Konieczny, 2002 ). An 8.5-kb sequence 5V to the rat Mrf4 gene similarly directs reporter gene expression in fetal muscles of transgenic mice and also in cells of the myotome (Pin et al., 1997) , suggesting that the first wave of Mrf4 transcription depends on element(s) situated between À8.5 and À6.5 kb from the gene. In addition, further upstream elements within 132 kb from the Mrf4 gene have been implicated, by deletion analysis, in aspects of its expression in the somite (Carvajal et al., 2001) .
Multiple regulatory sequences are therefore present throughout the Mrf4-Myf5 locus and this has complicated the interpretation of targeted mutations in either gene (see Olson et al., 1996; Yoon et al., 1997) . In addition, 3V exons of a large protein tyrosine phosphatase gene, Ptprq (Wright et al., 1998) , lie upstream (À23 kb) of Mrf4. This gene is not expressed in skeletal muscle, indicating that it is regulated independently. It is not yet clear to what extent sequences identified in the context of either Myf5 or Mrf4 regulation may affect the promoter of the other myogenic factor gene. Deletions of large YACs or BACs with nlacZ targeted to Myf5, which recapitulate expression of the endogenous gene, demonstrate that the intergenic epaxial enhancer and the À58/À48 kb region are essential for important aspects of Myf5 transcription in the embryo (Hadchouel et al., 2003; Teboul et al., 2002) . Mrf4 does not appear to be expressed in the epaxial dermomyotome, and therefore is probably not regulated by the early epaxial enhancer, and although the À58/À48 kb sequence may interact with the Mrf4 promoter, it does not do so to the same extent, given the differences in expression levels of the two genes in early limb muscles, for example (see Tajbakhsh and Buckingham, 2000) . The different expression profiles of Mrf4 and Myf5 would point to mechanisms of enhancer -promoter selection.
We describe here an alternative strategy to the long range YAC/BAC deletion approach for identifying regulatory sequences around the Mrf4-Myf5 locus. Based on an enhancer trap assay in cultured muscle cells, we have isolated a sequence (A17) situated at À17 kb from Myf5, which acts as an enhancer, with a 15-bp core sequence containing a critical E-box that binds USF complexes. In vivo, this enhancer is active, directing an nlacZ transgene with a nonmyogenic Tk promoter either to the early intercalated myotome or later to fetal muscle fibers. The mutual exclusion of these two modes of expression is also seen with the Mrf4 and Myf5 promoters; with the former, the enhancer tends to follow the first mode whereas with the latter the enhancer only directs expression in muscle from fetal stages in the transgenic lines analyzed. These results have implications both for the regulation of myogenesis at the sites targeted by the enhancer and for promoter/enhancer interactions in the Mrf4 -Myf5 locus.
Materials and methods

Cell culture and transfections
C2/7 myoblasts (Yaffe and Saxel, 1977) and 10T1/2 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco) containing 20% fetal calf serum (FCS) (Gibco). U2OS osteosarcoma cells were grown in DMEM containing 10% FCS. C2 myoblasts in confluent cultures were induced to differentiate into myotubes by changing to DMEM/2% FCS. Cells seeded onto 60-mm dishes (Falcon) were transfected by the calcium phosphate method as described in Chang et al. (1997) . Transfection of myotube cultures was performed 5 days after switching to differentiation medium. Typically, 10 Ag of reporter plasmid was cotransfected with 1 Ag of pRSV-luciferase (Biben et al., 1994) per dish as a control for transfection efficiency, and cell extract harvested for quantification as described in Kelly et al. (1997) . h-Galactosidase and human placental alkaline phosphatase activity of extracts were quantified using the GalactoLight and PhosphaLight chemiluminescent reporter kits (Tropix, Bedford, MA), respectively, according to manufacturer's instructions. Luciferase activity was performed as described in Biben et al. (1994) , and all luminescent samples were measured in a Lumat LB9501 luminometer. C2 cell injections were performed as described in Lazaro et al. (1997) , and stable G418-resistant clones selected for 10 days in 700 Ag/ml G418 (Gibco).
Fluorescent in situ hybridization (FISH) analysis
Cells of C2-YAC clones were arrested at metaphase by addition of colcemide for 2 h (Serva). Chromosome spreads were prepared by repeated fixation of cells with 1:3 acetic acid/methanol and spreading cells on precleaned glass slides (see Kappler et al., 1998 for details) . FISH was performed as in Scherthan et al. (1994) , but total YAC DNA was prepared and biotin-labeled using a BioNick nick translation kit (Life Tech). Labeled DNA (300 ng) was suspended in 10 Al of hybridization solution (50% formamide, 2Â SSC, 10% dextran sulfate, 4 mg/ml mouse Cot1 DNA). Slides and probes were denatured separately at 70jC for 3 min and hybridization solution was applied to the slide. After 48-h hybridization, preparations were washed and hybrid molecules detected with avidin-FITC (Sigma). Two-color FISH with biotinylated mouse chromosome 10 paint probe (Oncor P6110-B.5) and digoxigenin-labeled YAC probe was performed in similar fashion (Kappler et al., 1998) . Chromosomes were embedded in Antifade solution (Vector) containing 0.5 Ag/ml DAPI as DNA-specific counterstain and analyzed using a Zeiss Axioskop fluorescence microscope. Pictures were recorded with ISIS software (MetaSystems) controlling a CCD camera (Hamamatsu).
Plasmid construction and mutagenesis
The Myf5-nlacZ reporter plasmid was constructed by subcloning a 3.5-kb XbaI promoter-nlacZ fragment of the Myf5 targeting construct as in Tajbakhsh et al. (1996b) in the XbaI site of pBluescript II SK(À) or pSK (Stratagene), followed by an SV40 polyA signal inserted in the SpeI site. The Mrf4-AP reporter plasmid was constructed by inserting a PCR-amplified, 385-bp mouse Mrf4 promoter in front of the human placental Alkaline Phosphatase-SV40 polyA cassette used in Sharpe et al. (1998) , into pSK from the XbaI site to the EcoRI site. The Tk-nlacZ reporter plasmid is as described in Hadchouel et al. (2003) . For all reporter constructs, enhancer elements were inserted at NotI sites upstream of the reporter. The A17 enhancer was PCR amplified from its pTk-GFPneo trap vector ) using primers containing a 5Vflanking NotI site (5V-CCGCTCGAGGCGGCCGCG-GGATCCCTGGTCATATGAAACAC-3V) and a 3V flanking EagI site (5V-CCGGATCCACGGCCGAGATCACATG-GCACATATTTGGTT-3V). The Myf5 proximal branchial arch enhancer (NheI-BsaBI fragment as described in Summerbell et al., 2000) was PCR amplified, similarly adding flanking 5V NotI and 3V EagI sites. Amplified fragments were digested with EagI for ligation into vector NotI sites, conserving only a 5V NotI site for successive insertions, and products of PCR amplification were verified by sequencing (Genome Express, Montreuil, France). An identical PCR strategy was used to generate A17 deletion mutants at the chosen nucleotides. In the case of A17D, nucleotides 1 to 508 were PCR amplified with a flanking 5V NotI site and a fused 3V XbaI site and inserted into pSK. Subsequently, nucleotides 526 -583 were amplified with a flanking 3V EcoRI site and fused 5V XbaI site and inserted into the intermediate construct to generate a core-deleted A17D mutant such that nucleotides 509 -525 are replaced by an adenosine residue.
Site-directed mutagenesis on A17 was performed from a pSK-A17 plasmid using a PCR-based QuikChange mutagenesis kit (Stratagene) and oligos with complementary mutations in this sequence: 5V-GTCGGTAAGTTTCTTA-TAGTTGATTGACTCACATGACGTGCTTTGTTTAAC-3V. A17 mutants were screened by restriction assays, verified by sequencing, and subcloned into reporter constructs.
Gel mobility shift assay (GMSA)
The 31-bp, double-stranded GMSA probe spanning the wild-type A17 core was generated by annealing a 29-bp sense oligo (5V-AGTTTCTTATGATTGACTCACATGACGTG-3V) with a 29-bp antisense oligo (5V-AGCACGTCATGT-GAGTCAATCATAAGAAA-3V) such that the 5V single-stranded overhanging AG nucleotides were filled in by incubation with Klenow polymerase (New England Biolabs) and radiolabeled [a 32 P]-dCTP and [a 32 P]-dTTP (Amersham) for 1 h at 37jC. Probes and nonradioactive cold competitor dsDNAs were purified in Chromaspin-10 gel filtration spin columns (Clontech). Mutated probes and cold competitors, as indicated in the results section, were generated in identical fashion. C2 nuclear extract was prepared as described in Schreiber et al. (1989) , and procedures for binding extract to probe, and polyacrylamide gel electrophoresis were as described in Catala et al. (1995) . Three micrograms of protein extract (quantified by Bradford assay) and 2 ng of labeled probe per reaction were used. In supershift assays, 1 Al of antibody solution was added and incubated with the reaction for 10 min on ice before addition of labeled probe. Antibodies used were purified rabbit antisera against Myf5 (48234; Cterminal, as used in Kitzmann et al., 1998) and Mrf4 (48185; C-terminal), antisera against domains F, G, M, and Z of USF1 or USF2 as described in Viollet et al. (1996) , and monoclonal antibodies against Myogenin (Wright et al., 1991) , against Pbx1/Pbx2/Pbx3 (sc888X supershift reagent, Santa Cruz Biochemical), and against murine MyoD1 (M3512, Dako).
Mouse transgenesis, embryo staining, in situ hybridization
Transgenic mice were generated by microinjection of purified DNA fragments into fertilized (C57BL/6J X SJL) F2 eggs using standard techniques, as described in Hadchouel et al. (2000) . Injected eggs were reimplanted the day after injection into pseudopregnant (C57BL/6J X CBA) F1 foster mothers. Transgenes were identified by PCR from mouse tails using a primer situated in lacZ as described in Tajbakhsh et al. (1997) , paired with a primer situated in the promoter of either Myf5 (Tajbakhsh et al., 1997) 
Transgene expression was analyzed as described in Hadchouel et al. (2000) , and in situ hybridization on transgenic embryos was carried out as in Tajbakhsh et al. (1997) , except that the embryos were X-gal stained (Tajbakhsh et al., 1997) before overnight fixation in 4% PAF and subsequent hybridization. Controls to show the full extent of Myf5 expression were either the Y200-Myf5-nlacZ YAC line (Hadchouel et al., 2000) or Myf5-nlacZ heterozygotes in which one allele of Myf5 had been targeted with nlacZ (Tajbakhsh et al., 1996a,b) . The En1 in situ probe was as described in Acampora et al. (1998) . All images were generated either by scanning (Polaroid SprintScan35) Kodak Ektachrome 64T slides or captured by a Zeiss Axiocam CCD camera using Zeiss Axiovision 3.0.6 SP3 software.
Results
An enhancer trap assay was devised to screen for small, positive DNA regulatory elements in the Mrf4 -Myf5 locus, which are active in muscle cells . A Yeast Artificial Chromosome (YAC) containing 190 kb of mouse genomic sequence upstream and 10 kb downstream of Myf5 had been targeted at the ATG of Myf5 with the nlacZ reporter gene that expresses nuclear localized hgalactosidase. In transgenic mouse embryos, the expression profile of YAC y200-Myf5-nlacZ recapitulates that of Myf5, demonstrating that the elements required for Myf5 regulation in vivo are contained in the YAC (Hadchouel et al., 2000) . A Bacterial Artificial Chromosome (BAC) with a similar mouse genomic sequence was shown to be sufficient for directing correct expression of the closely linked Mrf4 gene as well (Carvajal et al., 2001 ).
Since the screen for regulatory elements contained within the YAC was to be performed in the mouse C2 muscle cell line, we first tested for reporter expression in C2 myoblasts, which express Myf5. The YAC used contains a neo selectable marker gene, permitting the selection of C2 cells that have incorporated it into their genome. When stained with X-gal, G418-resistant colonies were h-galactosidase-positive (blue) (Figs. 1A -B), thus confirming that sequences necessary for Myf5 transcription in C2 cells are present in the YAC. Previous transfections using 5.5 kb of Myf5 upstream sequence showed that this is essentially inactive in these cells (S.T. unpublished). To ensure that the YAC had not recombined homologously into the endogenous Mrf4 -Myf5 locus, FISH (fluorescent in situ hybridization) analysis was performed on the chromosomes of normal C2 myoblasts and of seven different clones, using a YAC-containing yeast DNA as a Myf5 probe and a mouse chromosome (MMU) 10 paint probe, which marks the chromosome containing the endogenous Myf5 gene. Twenty well-hybridized metaphase preparations were scored for signals. In all clones tested, the Myf5 probe (red) colocalized with the paint signals (green) of the four endogenous chromosomes 10 of the tetraploid C2 cell line (Fig. 1C) , and in addition, we noted a Myf5-specific signal on a different chromosome denoting the ectopic integration site of the YAC (Fig. 1D ). This demonstrates that the YAC integrated in a nonhomologous chromosome in the genome of the C2 cell clones where it directs nlacZ expression from its own myogenic regulatory elements. The FISH experiments with the YAC clone revealed only one FISH signal at MMU 10D1, the endogenous Myf5 locus, indicating that the Myf5 YAC used in the experiments was specific for this locus.
Fragments of purified y200-Myf5-nlacZ YAC DNA were generated by a Sau3A partial digestion, and size-selected through Sepharose spin columns to yield fragments of 2 kb or smaller. A library was created by inserting these fragments into the BamH1 site of a pTk-GFPneo trap vector in front of the minimal promoter of the Thymidine kinase (Tk) gene from Herpes Simplex virus (see Luckow and Schutz, 1987) . The insertion of an enhancer directs expression of a GFP-neo fusion protein that permits an antibiotic-or fluorescent-based selection of positive clones. In the C2 cell system, stable transfection of similar constructs containing the CMV enhancer or the 256-bp MyoD core enhancer (Goldhamer et al., 1995) produced an increased number of colonies and an increased average size of stably selected clones, easily discernable visually .
The YAC-trap library was transformed into bacteria and individual colonies gridded out at 200 -250 colonies per transformation. Assuming an average fragment size of 1 kb, seven such transformations would yield a total pool of about 1500 colonies with a total DNA content of 1500 kb, essentially covering the y200-Myf5-nlacZ sequence 7-fold. DNA was purified from each pool of approximately 200 colonies and transfected into C2 cells, which were selected for 7 days in G418, fixed and stained on the dish with crystal violet to visualize colony size and number. Two such pools, A and G, demonstrated slightly above average colony-forming efficiency, compared to a control transfected with pTk-GFPneo. From replica plates of dishes containing pool A and pool G, plasmid DNA was harvested from quadrants representing approximately 50 clones, and each of these subpools was again stably transfected into C2 cells. By reiterating this process of positive subpool selection, single colonies that gave a positive signal in C2 cells were finally obtained.
Their DNA was sequenced and mapped onto y200-Myf5-nlacZ by Southern blot analysis. The most active of the enhancer clones (A17) was captured twice independently, and mapped to À17 kb from the Myf5 ATG. The remaining clones were discarded either because they were part of a mouse genomic LINE1 repeat element (situated À75 to À66 kb 5V of Myf5) or else mapped too far from the Myf5 gene, and by inference Mrf4 as well, to be implicated in their regulation, based on knowledge obtained from successive YAC deletions (Hadchouel et al., 2000) .
Enhancer characterization in vitro
The mouse DNA sequence in A17 corresponds to a 583-bp Sau3A fragment that contains several potential transcription factor binding sites ( Fig. 2A) . To assay enhancer activity, the fragment was subcloned into nlacZ reporter vectors driven by either the 170-bp Tk minimal promoter used previously, the 291-bp Myf5 minimal promoter (Summerbell et al., 2000) , or the 385-bp Mrf4 minimal promoter (Black et al., 1995) . Reporter gene expression, measured as h-galactosidase activity and corrected for transfection efficiency using an RSVluciferase control vector, was typically increased 10-to 30-fold, compared to the promoter alone, in the presence of the A17 sequence with all three minimal promoters in C2 muscle cells. This was comparable to the increase seen with the MyoD core enhancer (Goldhamer et al., 1995) or the RSV enhancer (Gorman et al., 1982) in parallel experiments. The A17 sequence also functioned, with about one-third efficiency, when inserted into an nlacZ expression vector in the opposite orientation. Enhancer activity was not confined to muscle cells, but was also seen with 10T1/2 mouse embry- Fig. 1 . C2 muscle cells express the YAC from a nonhomologous integration site distinct from the Mrf4 -Myf5 locus. (A, B) C2 cells injected with y240-Myf5-lacZ, in which Myf5 is targeted with a lacZ reporter gene, show h-galactosidase activity in G418 selected colonies, such as YC108 (A) and YC20 (B). Scale bars represent 10 Am. The y240-Myf5-lacZ YAC used in these early experiments gives the same expression profile in vivo as YAC y200-Myf5-nlacZ (Hadchouel et al., 2000) . (C, D) Painting of mouse chromosomes 10 by FISH (FITC, green) and FISH with the Myf5 YAC (rhodamine, red) identifies the endogenous Myf5 locus at MMU 10D1 (arrows) in a tetraploid C2 cell (C, control). In a C2 cell, which has been injected with y240-Myf5-lacZ, such as in clone YC103, the YAC integration occurred on another mouse chromosome where it creates a strong red FISH signal (yellow arrowhead) (D, 103). The round structure in the center of the lower image corresponds to an interphase nucleus.
onic fibroblasts (about 10-fold activation) and with U20S osteosarcoma cells (about 50-fold activation). In cultures of differentiated C2 myotubes, in contrast to C2 myoblasts, the A17 sequence only gave a twofold enhancement at most with the Myf5 minimal promoter. When linked to a reporter construct expressing the human placental Alkaline Phosphatase reporter gene from the Mrf4 minimal promoter, a consistent 5-fold enhancement was seen in the presence of A17. A series of deletions of A17 from both the 5V and 3V end were assembled using PCR-amplified subfragments and cloned into a Myf5 minimal promoter-nlacZ reporter vector. The activity of these fragments relative to the whole A17 sequence shows that 120 bp at the 3V end are both necessary and sufficient for enhancement of reporter gene expression in C2 myoblasts (Fig. 2B ). More 5V sequences may contain elements which repress A17 activity.
Within this 120-bp sequence, there are several transcription factor binding motifs ( Fig. 2A) . Notably, a 15-bp sequence contains a candidate homeodomain binding site overlapped by an AP-1 site, which in turn overlaps with an E-box motif. A mutation (A17D) in which this 15-bp core (nucleotides 511-525) is replaced by a single adenosine residue (to reconstitute an XbaI site for diagnostic purposes) in the context of the complete 583-bp enhancer was constructed and measured for enhancer activity. A17D showed no significant enhancer activity relative to an nlacZ reporter construct with the promoter alone, thus identifying the 15-bp core as critical for activation (Fig. 2C) . The 120-bp 3V fragment of A17 is necessary and sufficient for enhancer activity. 5V and 3V deletions of A17 were cloned into a Tk-promoter nlacZ reporter construct and assessed for enhancer activity by transfection into C2 myoblasts. Enhancer activity relative to the 583-bp control (100%) is shown for a typical trial. Transfection efficiency has been normalized relative to an RSV-luciferase control. The results shown are the average of duplicate measurements in a typical experiment. Similar results were obtained in five other series of transfections. (C) The E-box in the 120-bp fragment is critical for A17 enhancer activity. Point mutations within the 120-bp fragment, with the substituted bases shown in lower case, were created in the context of the whole 583-bp enhancer, and cloned into a Myf5 minimal promoter (291-bp)-nlacZ reporter construct for assessment of enhancer activity. Relative activities of constructs carrying mutations destroying the homeodomain binding site (HD), AP-1 site (AP), E-box (E), or combinations thereof, are indicated for a typical trial. Activity of the unmutated sequence is taken as 100%. Transfection efficiency has been normalized relative to an RSV-luciferase control. The results shown are the average of duplicate measurements. Similar results were obtained in nine other experiments.
Site-directed mutagenesis of bases in the core sequence were designed to disrupt the homeodomain site only (M1), the homeodomain site and AP-1 site (M2), the AP-1 site only (M6), the AP-1 site and E-box (M3), the E-box only (M4), or all of these sites (M5). The activity of these constructs in C2 myoblasts is shown in Fig. 2C . The mutation affecting all these sites (M5) abolished enhancer activity. Mutations affecting the homeodomain (e.g., M1, M2) tended to increase activity. Mutation of the AP-1 site (e.g., M2, M6), which should abolish all activity (Schüle et al., 1990) , had little or no effect, whereas a mutation that affected the AP-1 site and the E-box (M3) reduced reporter gene expression to the level seen when the 15-bp core sequence was deleted (A17D). Mutation of the E-box alone (M4) reduced but did not abolish enhancer activity.
To examine protein binding to these sites in the 15-bp core sequence, electrophoretic gel mobility shift assays (GMSA) were performed on a 3V end-labeled, 31-bp double-stranded oligonucleotide spanning the core sequence, using nuclear extract prepared from C2 myoblasts (Fig. 3A) . Two shifted complexes, A and a doublet B, were competed by the identical unlabeled oligonucleotide. Neither complex could be competed by the mutant sequence M5, at up to 100-fold excess. Mutant M3, which affects the E-box and AP-1 site, shows very little competition of complex A. A competitor oligonucleotide in which the internal nucleotides of the E-box are deleted (DE) is still capable of competing complex B but does not affect complex A. Another competitor oligonucleotide, deleted for the core of the AP-1 site (DAP) but not affecting the E-box, competes complex A and almost all of B, strongly suggesting that the AP-1 site is dispensable for protein binding. GMSA assays, using the same mutant sequences as labeled probes, confirmed that the E-Box is required for binding of complex A and that the AP-1 site is dispensable for binding of all observed complexes (Fig. 3A) . Since oligonucleotide M5, which is mutated for all three binding sites, does not bind either complex as a probe and cannot compete either complex as a competitor, it is inferred that complex B must bind the homeodomain site of the 15-bp core, as indicated by binding to the M3 mutant sequence (Fig. 3A) .
Gel supershift assays were performed with antibodies against candidate binding proteins to elucidate the composition of the complexes and particularly complex A (Fig. 3B) . Antibodies against the myogenic regulatory factors Myf5, Mrf4, Myogenin and MyoD, which bind to E-boxes (reviewed in Weintraub et al., 1991) failed to shift either complex A or B. They also did not transactivate the A17 enhancer (results not shown). Since both experiments were Fig. 3 . A USF complex binds to the E-box in the 15-bp core of the A17 enhancer. (A) A radioactive (**) wild-type probe spanning the 15-bp core (boxed) of the A17 enhancer binds complex A and a doublet, complex B, in gel mobility shift assays (GMSA) with C2 myoblast extracts. These are competed by increasing concentrations (10Â, 50Â, 100Â) of the cold probe itself (wt) and of DAP, which contains a deletion (ACT) that eliminates the AP-1 site. In contrast, M5, in which all the candidate-binding sites are mutated (Fig. 2C) , does not compete. M3 (Fig. 2C) , in which the AP-1 and E-boxes are mutated, eliminates complex B, but only slightly affects complex A. DE, is an oligonucleotide of the wild-type sequence with a deletion (CAT) in the E-box, which does not compete complex A. Mutant radioactive probes corresponding to M3 and DE do not bind complex A compared to the unmutated A17 enhancer (wt). A radioactive DAP probe binds both A and B whereas M5 binds neither. With DE and DAP, an additional complex migrates more slowly than A. (B) GMSA are shown with the radioactive wildtype probe. Complex A can be supershifted by antisera against USF1 (M) or USF2 (F, G, Z), but not preimmune serum (PI). Antibodies against Pbx1/Pbx2 (Pbx), and myogenic regulatory factors Myogenin (Mg), MyoD (Md), Mrf4 (M4) and Myf5 (M5) do not supershift the core binding complexes. (C) Enhancer activity in C2 myoblasts transfected with 10 Ag of an A17-Tk-nlacZ construct (taken as 100%) is downregulated in a dose-dependent manner by cotransfection of dominantnegative (dn) USF1 (TDU1) or USF2 (TDU2) expression plasmids, deficient in transactivation. Transfection efficiency is normalized relative to RSV-luciferase activity. Results with 5 Ag are the average of two experiments each with duplicate measurements. SEM indicated with error bars. performed under conditions in which the standard E-box from the Creatine Phosphokinase enhancer responds positively, these results suggest that the E-box in the core sequence is not regulated by the myogenic factors. Pbx homeodomain complexes have a consensus binding site similar to that of the homeodomain site in the enhancer core (Knoepfler and Kamps, 1997 ) but antibodies to Pbx also did not give a shift with either complex A or B. In contrast, antisera specific to either USF-1 or USF-2 were both capable of shifting nearly all of complex A in the supershift assay.
USF transcription factors (Sawadogo and Roeder, 1985 ) bind E-boxes as homodimers, heterodimers of USF1 and USF2, or as heterodimers with other bHLH-Leucine zipper transcription factors. Because USF dimers bind DNA and transactivate promoters through different and separable domains, dominant-negative (dn) USF expression vectors have been constructed, which are either deficient in transactivation (TDU1 and TDU2) or deficient in transactivation and DNA-binding (DbTDU1 and DbTDU2) (LefrancoisMartinez et al., 1995) . Ectopic overexpression of these mutants, which retain the ability to dimerize through their HLH-Leucine Zipper domain, titrates endogenous activity of USF and USF-partner proteins. Cotransfection of transactivation deficient mutants of either USF1 (TDU1) or USF2 (TDU2) along with an A17-Tk-nlacZ reporter construct in C2 myoblasts was sufficient to extinguish enhancer activity in a dose-dependent manner (Fig. 3C) . A similar result was obtained with the DNA-binding defective mutant (not shown). This implies that the USF family of transcription factors bind the E-box in the core sequence of the enhancer and may be responsible for its transactivation in C2 cells. Cotransfection of wild-type USF1 and USF2 expression vectors did not increase transactivation (data not shown), which we attribute to large endogenous pools of USF proteins present in C2 cells.
A17 enhancer activity in vivo
To obtain a first indication of A17 enhancer activity in vivo, transient transgenic embryos with the A17-Tk-nlacZ fragment were assayed for activity at embryonic day (E)11.0. h-Galactosidase activity was seen in a subregion of the epaxial myotome following the rostral-caudal gradient of somite maturation (Fig. 4A) . We therefore developed lines with the 583-bp A17 enhancer directing nlacZ expression in conjunction with the Tk, Myf5, or Mrf4 minimal promoters used previously. About 70% of PCR-positive transgenic lines did not express the transgene, suggesting that the enhancer sequence may be subject to integration site silencing. Four A17-Mrf4-nlacZ lines, three A17-ba-Myf5-nlacZ lines, and one A17-Tk-nlacZ line were produced, which showed enhancer activity.
Transgene expression was also tested after deletion of the 15-bp core sequence from the A17 enhancer (A17D). In this case, the element (ba) at À1.8/À0.7 kb from the Myf5 ATG, which drives reporter gene expression specifically in the branchial arches (Summerbell et al., 2000) , was placed in front of the Tk minimal promoter to provide an internal positive control. In five transient transgenic embryos, in which the transgene was expressed correctly in the branchial arches, no additional myogenic expression was seen at E10.5 (Fig. 4B) .
Of the four Mrf4 promoter (À385 bp) lines, three express the nlacZ reporter in embryonic myotomes. Two lines, 43M and 44F, are phenocopies and presented in Fig. 4C . X-gal staining is first detectable in the epaxial myotome at E8.75 (15 somites), when a few h-galactosidase positive cells are seen in the more mature rostral somites, from about somite XII, where somite I is the most recently formed (results not shown). At E10.75 and E11.5, the transgene continues to be expressed in myotomes from somite X as seen at E9.75. At E11.5, weak hypaxial expression was also detected in addition to strong epaxial labeling. h-Galactosidase activity is gradually lost in the most mature somites as development proceeds. At E12.5, there is residual X-gal staining more rostrally, but only the more caudal somites from the hind limb level are still strongly expressing the transgene. By E14.5, no h-galactosidase-positive cells are detectable except in tail somites (results not shown). As seen in Fig. 4C , only a subdomain of the myotome is labeled at E11.5, compared with an embryo where transgene expression is directed by all the regulatory sequences present in YAC y200-Myf5-nlacZ (Fig. 4D ). This central epaxial territory resembles that of the intercalated domain, characterized by the extent of Engrailed1 expression in the dorsal somite (Spörle, 2001) . To examine this more closely, E10.75 embryos of line 43M were stained with X-gal and subsequently hybridized in situ with an Engrailed1 riboprobe (purple). Cells expressing the transgene, which are h-galactosidasepositive, lie within the Engrailed1 expression domain (Fig.  4F) , and thus constitute a subdomain of Myf5 expression in the myotome (Fig. 4E) . The third A17-Mrf4-nlacZ line, 1F, with X-gal staining in the myotome, shows much higher levels of transgene expression. The full extent of the myotome is labeled and there is also ectopic expression in the neural tube and dorsal root ganglia (results not shown). Myotome labeling outside the intercalated domain may correspond to lower levels of h-galactosidase activity, which are not easily detectable in the other two transgenic lines, perhaps reflecting persistence of the protein in cells that no longer transcribe the transgene. In line 1F, also, labeling in all but the least mature somites is no longer detectable by fetal stages of development (E13) (results not shown). The expression profile, characterized by myotomal labeling in the embryo (Fig. 4) , reflects the first wave of Mrf4 expression Hinterberger et al., 1991) , which in these A17-Mrf4-nlacZ (and A17-Tk-nlacZ) transgenes is uncoupled from later fetal expression. The fourth A17-Mrf4-nlacZ line, 4M, expresses the transgene only in fetal muscle from E13.5. In Fig. 5B , an E14 fetus shows strong Xgal staining in proximal limb muscles, and in back muscles and muscles of the neck and head.
The three A17-ba-Myf5 promoter lines (52M, 54M, and 56F) included the proximal element (À1.8/À0.7), which drives expression in the branchial arches linked to the 291 bp Myf5 promoter (Summerbell et al., 2000) , as a positive control for embryonic expression of the transgene. None of these lines showed X-gal staining of myogenic cells in the embryo except in the branchial arches (Fig. 5D) . The line 56F expresses the transgene as well in the neural tube. Line 52M displayed ectopic expression in neural crest derivatives, and 54M in presomitic mesoderm (results not shown), but not restricted to the region where low level expression was observed in embryos with nlacZ targeted to the Myf5 gene (Cossu et al., 1996) . However, all three lines expressed the transgene in fetal muscles. X-gal staining on whole-mount embryos (Figs. 5E and F) , at E14.5 shows labeling of limb muscles, body muscles, including the intercostals and rectus abdominus (arrows), and neck and head muscles. The branchial arch element probably also contributed to jaw muscle expression (cf. Figs. 5A,B ; Noden, 1983) . Not all muscles appear to be labeled to the same extent, notably those in the more distal limb, and body wall muscles, compared to a control y200-Myf5-nlacZ embryo at the same stage (Fig. 5C ). By E17.5, when transverse cuts of the fetus were made to facilitate X-gal staining, most major body muscle masses are strongly labeled (results not shown). The effect of deleting the core sequence of the enhancer (A17D) was also examined at fetal stages with the Myf5 promoter. At E14.5, no skeletal muscle expression in the trunk or limbs was observed in ten transgenic embryos, six of which showed some h-galactosidase labeling at ectopic sites. One embryo showed low-level labeling in a few skeletal muscles (results not shown). These results suggest that the core sequence plays a role in enhancer activity in vivo, in fetal as well as embryonic skeletal muscle.
The A17-ba-Myf5-nlacZ lines (and one A17-Mrf4-nlacZ line and the A17-Tk-nlacZ line) have a fetal expression profile similar to that described for the second wave of Mrf4 transcription Hinterberger et al., 1991; Patapoutian et al., 1995) , uncoupled from the earlier embryonic wave.
Discussion
An enhancer trap approach in the C2 muscle cell line has led to the isolation of a mouse genomic sequence in the 5V flanking region of the Mrf4 -Myf5 locus. In vivo, this enhancer (A17) directs muscle specific expression of a reporter gene either in the embryonic myotome or in later fetal muscle. These two alternate modes are observed with a nonmuscle Tk promoter while Mrf4 and Myf5 promoters preferentially direct early or late expression, respectively, in the transgenic lines examined.
The C2 cell line was derived from the limb muscle of newborn mice (Yaffe and Saxel, 1977) . Undifferentiated myoblasts express Myf5 and MyoD and in the cells used in these experiments, Mrf4 was also detectable (M.P., unpublished). When the cells differentiate, transcripts of MyoD, Myogenin and Mrf4, accumulate (Montarras et al., 1991) . The enhancer trap assay was aimed at isolating Myf5 regulatory sequences and therefore genomic fragments were screened in myoblasts. Apart from repeat sequences resulting from LINE1 retroviral insertions, only the A17 sequence, which was isolated twice, had activity, within the 96-kb region upstream of Myf5. A17 is active with Tk (À170 bp), as well as Myf5 (À291 bp) and Mrf4 (À385 bp) minimal promoters, and in the reverse orientation, consistent with enhancer function. Several other sequences that are active with heterologous promoters as well as that of Myf5 have been identified in this region, notably at À58/À48 kb (Hadchouel et al., 2000 (Hadchouel et al., , 2003 and at À6 kb (Summerbell et al., 2000; Teboul et al., 2002) . These sequences showed no activity in C2 cells (results not shown). This may reflect their expression in vivo, which is confined to embryonic stages. In keeping with the expression of Myf5 in the C2 cell line, A17-Myf5-nlacZ, which shows 10-30-fold enhancement in myoblasts, is virtually inactive (2-fold) in differentiated myotubes. However, its activity in vitro is not confined to undifferentiated muscle cells; enhancement is also seen in other mesodermal cell lines. This is also the case for the MyoD enhancer located at À20 kb from the gene, which in vivo directs muscle specific expression and in vitro is active in C2 cells and in the 10T1/2 fibroblast cell line (Goldhamer et al., 1992) .
Further analysis of A17 activity in C2 myoblasts demonstrated that this depends on a 15-bp core sequence with three potentially interesting binding sites for homeodomain pro- teins, AP-1 (jun/fos) and b-HLH E-box binding factors. The homeodomain-binding site is identical to an optimized sequence that binds a putative myogenic factor COMP1, which cooperatively enhances Myogenin transactivation on an adjacent E-box (Funk and Wright, 1992) . This TGATT-GAC sequence also corresponds to the Pbx Consensus Element (PCE) defined for the Pbx family of proteins (Knoepfler and Kamps, 1997) , which are capable of cooperating with MRF complexes in DNA binding assays (Knoepfler et al., 1999) , but the experiments reported here suggest that other proteins are binding to this site (bands B), and may be exerting some repressor function in C2 myoblasts, since mutation of the site increases A17 activity. Although AP-1 has been implicated in the regulation of Myf5 (Aurade et al., 1997) , there was no indication that the AP-1 site in the A17 core is involved in binding activity. Sitedirected mutations indicated that the E-box is important for activity. However, there was no indication that myogenic factors regulate the enhancer through the E-box. Indeed, myogenic conversion experiments in nonmuscle cells show that the other myogenic factors cannot activate Myf5 (Aurade et al., 1994) and in the Myf5 mutant where nlacZ is targeted to both Myf5 alleles, the reporter gene is expressed correctly (Tajbakhsh et al., 1996a) , suggesting that autoregulation may not be a major consideration. A17 is also active with the promoter of Mrf4, a myogenic factor gene that can be activated by other myogenic factors, but part of this may take place via an E-box in the proximal promoter (Black et al., 1995) . USF binds to the E-box in the A17 core sequence and overexpression of dominant-negative forms of USF1 and USF2 in C2 cells repress A17 activity. USF factors are widely expressed in different tissue types and at different developmental stages. Single null mutations are viable with no obvious muscle phenotype, whereas the double USF1/ USF2 mutation is an early embryonic lethal (Sirito et al., 1998) and therefore uninformative about USF function in myogenesis. However, the observations on C2 muscle cells and the fact that deletion of the 15-bp core sequence from the A17 enhancer affects its activity in vivo, under conditions where the branchial arch control element present in the transgene is expressed, suggests a potential role for USF in the regulation of the Mrf4 -Myf5 locus in both embryonic and fetal muscle. Myosin light chain-2v, expressed in slow skeletal muscle, is regulated through a USF-binding site in its promoter (Navankasattusas et al., 1994) .
In vivo, the A17 enhancer directs transgene expression specifically in skeletal muscle. Some ectopic expression is seen with this short sequence, but it is variable between lines, reflecting integration site effects. Two modes of expression are observed, which appear to be mutually exclusive. With the Tk and Mrf4 promoters, expression is seen in embryonic skeletal muscle, in cells in the intercalated myotome. This region of the dorsal somite is marked by Engrailed1 expression (Spörle, 2001) . The early epaxial myotome assumes this more central position as the somite elongates and it is in this intercalated region that differentiation is initiated, probably by Mrf4 (see Buckingham, 1994) during its first phase of expression (Patapoutian et al., 1995; see also Smith et al., 1994) . In one line, which expressed the transgene at a high level, more extensive myotomal expression was seen. This may reflect persistence of h-galactosidase in cells that subsequently leave the intercalated domain, or low level Mrf4 expression in myotomal cells where the differentiation factor Myogenin preferentially accumulates (Smith et al., 1994) . The timing of A17 activity corresponds to that described for the early phase of Mrf4 expression (about E9.5-11.5). A transgene with À8.5 kb of DNA flanking the rat Mrf4 gene driving a lacZ reporter gene was expressed in the central myotome although, unlike A17-Mrf4-nlacZ, this was only detected in thoracic somites (Pin et al., 1997) . Since À6.5-kb flanking the mouse Mrf4 gene was not sufficient to drive myotomal expression (Patapoutian et al., 1993) , this is consistent with the presence of the A17 enhancer, situated at À8 kb from Mrf4. We have described a y23-Myf5-nlacZ transgene that is expressed in part of the intercalated myotome (Hadchouel et al., 2000) , possibly due to A17 activity, although we did not see embryonic muscle expression with A17-ba-Myf5-nlacZ transgenes. A second element, which also targets the intercalated myotome, is present at À57.5/À56.6 (Hadchouel et al., 2003) . This region of the somite is clearly a distinct regulatory domain. In our transgenic lines, we saw no indication of earlier expression in the hypaxial dermomyotome, where Mrf4 is first expressed along with Myf5 in muscle progenitor cells . Expression here is probably regulated by a distal element(s) at more than À88 kb from Myf5 (Carvajal et al., 2001) .
The second phase of Mrf4 expression in the fetus and adult (Patapoutian et al., 1995) is partially regulated by sequences within À8.5 kb of the rat Mrf4 gene (Pin et al., 1997) to some extent reflecting regulatory sequences in the À6.5-kb flanking region (Patapoutian et al., 1993) within which lie regulatory regions identified as active in C2 cells (Kerkvliet and Hinterberger, 1997) and in the mouse fetus (Pin and Konieczny, 2002) . The proximal Mrf4 promoter (À385 bp), which directs no somitic expression, shows very limited activity in a few fetal muscle fibers (Pin et al., 1997) . Transgenes with the A17 element show fetal muscle expression and an example of this was observed with both Tk and Mrf4 promoters, indicating that this is driven by the enhancer sequence. Not all fetal muscles are equally labeled, suggesting that other sequences are also necessary.
All three A17-ba-Myf5-nlacZ lines showed fetal and not embryonic expression of the transgene. Muscles in the head and neck and proximal limb muscles are most strongly labeled, but h-galactosidase activity is also detectable in trunk muscles such as the intercostals or rectus abdominus. The branchial arch element probably contributes to head and neck expression, although some of this is also seen with the Tk and Mrf4 promoter constructs. In the context of the locus, we had described a region between À96/À63 kb, which is required for the maintenance of Myf5-nlacZ expression in head and neck muscles and some body muscles such as the rectus abdominus (see also Carvajal et al., 2001; Hadchouel et al., 2000) . It is clear that the A17 element with the branchial arch sequence and Myf5 proximal promoter alone does not require this maintenance region for later expression, suggesting that either A17 does not normally direct Myf5 expression or that there are negatively acting elements elsewhere in the locus, which are overcome by the upstream maintenance sequence. Embryonic expression of Myf5, in the limbs and part of the somite, depends on the sequence at À58/À48 kb from the gene (Hadchouel et al., 2003) . However, at fetal stages, when this region is deleted in the context of a BAC covering 195 kb of the locus, Myf5-nlacZ expression becomes detectable in the limbs from E12.5, initially in proximal muscles of the forelimb. A17 is therefore a candidate regulatory sequence for this later phase of Myf5 transcription.
In conjunction with the Myf5 or Mrf4 promoter, A17 therefore reflects aspects of the expression of the corresponding genes. In the case of the Mrf4 and Tk promoters, both embryonic and fetal modes of expression were observed; however, in all the lines examined, these were always mutually exclusive. The molecular explanation for this striking observation is not clear. A DNAaseI hypersensitive site was detected at about À8 kb from the Mrf4 promoter in cultured C2 myoblasts (data not shown). This corresponds to the location of A17, suggesting that the enhancer is a target of chromatin regulation. The importance of chromatin remodeling during myogenesis is demonstrated by the role that Myf5 itself plays in modifying the repressive chromatin structure over regulatory regions of genes such as Myogenin (Gerber et al., 1997) . In the case of the A17 transgenes, chromatin modification may be influenced by the site of insertion, such that the onset of embryonic or fetal expression is affected. The second phase of expression does not appear to overlap with the first and may involve a different cell population, with distinct transcriptional requirements. The relatively low number of expressing transgenic lines might suggest that the enhancer is subject to silencing, which could lead to the absence of embryonic or fetal expression. This may be mediated by chromosomal proteins such as the HI linker proteins which inhibit MyoD induction in Xenopus, or histone modification which has been shown to regulate MyoD-and MEF2-mediated activation of muscle genes (see Rupp et al., 2002) . DNA methylation mediated silencing may also be acting on the transgenes. The distal enhancer of MyoD undergoes a regulated demethylation in somitic cells before the gene is activated in the mouse embryo, although methylation alone does not appear to account for the silencing of an enhancer regulated transgene in cells in which it is not normally expressed (Brunk et al., 1996; see Rupp et al., 2002) . Epigenetic mechanisms of these kinds are probably acting on the A17 transgene to varying degrees according to the integration site.
The tendency for A17-Mrf4-nlacZ transgenes to be expressed in embryonic muscle, while the A17-ba-Myf5-nlacZ lines obtained showed only later fetal expression, suggests that the enhancer -promoter combination is not neutral. Alone, the Mrf4 or Myf5 promoter sequences used do not direct significant reporter gene expression, but the implication is that they contain information which affects A17 activity. There are many loci where enhancer -promoter interactions have been studied in the context of the spatiotemporal regulation of gene expression during development. In the case of the HoxD cluster, a distant enhancer directs the expression of a given promoter according to its proximity; removing a gene (promoter) confers its expression pattern on the succeeding gene in the cluster (Kmita et al., 2002) . The Igf2-H19 locus provides another position-dependent model system, involving promoter competition for an endodermal enhancer. In this case, an intergenic chromatin boundary regulates promoter -enhancer interaction on an imprinted allele (Webber et al., 1998) . The h-globin cluster is a third example where looping out of intervening chromatin brings regulatory sequences in a distant locus control region into the proximity of a h-globin gene (Tolhuis et al., 2002) . In the case of the Mrf4-Myf5 locus, it is not clear how enhancers differentially affect the Mrf4 and Myf5 promoters. A simple linear model does not appear to apply since the À58/À48 enhancer region interacts with the Myf5 promoter to direct strong limb expression (Hadchouel et al., 2003) , although it is closer to the Mrf4 gene, which is not expressed strongly in the limbs at the stage when the enhancer is active. The results presented here suggest that where the A17 enhancer is concerned, the nature of the promoter, Mrf4 or Myf5, may influence the expression pattern. Further deletion experiments in the context of the locus will be necessary to clarify how the A17 enhancer contributes to the distinct expression profiles of Mrf4 and Myf5 during myogenesis.
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